A comprehensive portal site for Medical Innovation Support Office (MEDISO).Medical Innovation Support Office

Yutaka Kono

Guest professor
Drug Discovery Science Division,Institute for Open and Transdisciplinary Research Initiatives, Osaka University

Satoshi Fukushima

Globis Capital Partners & Co.

He graduated from the Faculty of Economics, University of Tokyo. He was involved in investment activities in reformed fields of existing industries, including digital health, at Globis Capital Partners & Co. (GCP). He served as an outside director of several companies, including Medley, Inc., Kakehashi Inc., and Yoriso. Co. Ltd., and provided support to their management personnel mainly in strategy formulation, development of the organization, and finance. In addition to investigation activities, he provided support for fund structuring and open innovations provided by large companies in healthcare fields.

Before joining GCP, he was serving as an M&A advisor mainly in the technology, media, and telecommunication fields and worked on financing at the general headquarters of German Securities Finance Corporation.

Takayuki Hirose

Patent attorney, Hirose International Patent Firm

He graduated with a master’s degree from the Graduate School, University of Tokyo. Patent attorney. After working in the intellectual property department in a major company, he was involved in lawsuit-, adviser- and application-relating services at a lawyer's office, followed by establishing his own international patent attorney's office in 2017. He offers intellectual property strategies in cooperation with companies as an adviser for multiple companies, including the Japanese Organization for Medical Device Development, Inc., (JOMDD) and Shin Nippon Biomedical Laboratories, Ltd. Furthermore, he applies for patent rights and trademarks in a wide variety of areas. He is involved in intellectual property-related services that include medical devices and pharmaceutical products. When he applies for a patent in foreign countries, he offers application strategies by placing the most importance on client’s profit, for example, to give advice to receive a subsidy or to select a foreign agent at a reasonable price depending on the company’s size.

Shunichi Takahashi

Bayer Yakuhin, Ltd.

After joining Mitsui Pharmaceuticals Co., Ltd., he worked at　Nihon Schering K.K., Berlex Biosciences (a US subsidiary of Schering AG). In 2007, he joined Bayer due to management integration. Over the past 15 years, he was in charge of exploring new projects and verifying concepts in drug discovery research, especially in the areas of cardiovascular systems, immunity, stem cell research, etc. Subsequently, he was in charge of the project management cardiovascular system area manager of development headquarters, the primary care manager of the medical affairs headquarters, and he has been in his current role since 2014 (Open Innovation Center director). He leads strategic partnerships and joint research with Japanese academies and venture companies. He is also verifying new pharmaceutical business models that take advantage of big data, AI, IoT, and others. In 2018, he launched the first venture incubation facility (CoLaboraotor Kobe) as a foreign-affiliated pharmaceutical company and is focusing on fostering ecosystems.

Satoshi Morimoto

Morimoto Phrma Partrnering, Representative

Representative of Morimoto Pharma Partnering. Master of Science in Applied Biochemistry, Graduate School of Waseda University. I stared my carrier at the former The Green Cross Corporation (now Mitsubishi Tanabe Pharma Corporation), experienced in pharmaceutical R&D, product strategy planning, and business development. During that time, I was dispatched as the liaison to Germany for four years. My last position was Director of Business Development. Then, I joined to CMIC Holdings, where I led the business development of rare disease drugs as Director of Business Development and Head of IPD Company. From 2016, I spent six years at the Mitsubishi Chemical Group's Life Science Institute(LSII) as head of the Regenerative Medicine Division, where I was involved in the early stages of cell product development, initiating clinical trials, and leading the construction and operation of cell processing facilities.　After retiring from LSII in 2021, I started own business as a consultant. I would like to provide practical advice based on my experience in the development and commercialization of rare disease drugs and regenerative medicine products. In addition, I would like to provide practical advice on business development from the perspective of having been introduced to various projects from venture companies over 30 years.